| Grant ID | DP240240 |
| Awarded On | May 15, 2024 |
| Title | CBB-120, a next-generation dual-payload antibody-drug conjugate for the treatment of TROP-2+ solid tumors |
| Program | Product Development Research |
| Award Mechanism | Seed Awards for Product Development Research |
| Institution/Organization | Crossbridge Bio, Inc. |
| Principal Investigator/Program Director | Michael Torres |
| Cancer Sites | Bladder, Breast, Lung and Bronchus |
| Contracted Amount |
$2,575,275* *Pending contract negotiation |
| Lay Summary |
CrossBridge Bio, a Houston-based biotech company, specializes in developing advanced antibody-drug conjugates (ADCs) targeting various cancers such as breast, lung, ovarian, and bladder. Current-generation ADCs, while revolutionary, face challenges like premature payload loss and resistance by cancer cells. CrossBridge Bio's solution, leveraging technology from UT-Health Houston, includes a proprietary linker offering greater stability and the ability to attach multiple payloads. This innovation potentially makes it harder for cancer cells to develop resistance. Early preclinical data in cancer cell and animal models supports this. The company's leading project focuses on TROP-2, a protei... |